Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway. NJPS [Internet]. 31. prosinac 2025. [citirano 15. travanj 2026.];40(2):251-62. Dostupno na: https://www.ojshostng.com/index.php/njphysiologicalsciences/article/view/4001